Affordable Access

A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection

  • Andreakos, Evangelos;
  • Abel, Laurent;
  • Vinh, Donald C;
  • Kaja, Elzbieta;
  • Drolet, Beth A;
  • Zhang, Qian;
  • O'Farrelly, Cliona;
  • Novelli, Giuseppe;
  • Rodriguez-Gallego, Carlos;
  • Haerynck, Filomeen;
  • Prando, Carolina;
  • Pujol, Aurora;
  • Su, Helen C;
  • Casanova, Jean-Laurent;
  • Spaan, Andras N;
  • Bastard, Paul;
  • Biggs, Catherine M;
  • Bigio, Benedetta;
  • Boisson, Bertrand;
  • Bolze, Alexandre;
  • And 33 more
Publication Date
Oct 18, 2021
External links


SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection. / status: published

Report this publication


Seen <100 times